In this episode of NCL’s “We Can Do This” podcast, we dive into the world of biosimilars—cost-effective alternatives to expensive biologic drugs. Host Sally welcomes Giuseppe Randazzo (Association for Accessible Medicines) and Anna Hyde (Arthritis Foundation) to discuss the urgent need to simplify the biosimilar approval process. Discover how regulatory modernization could save billions, improve patient access, and break down barriers in the healthcare system.

Our experts explain the challenges patients face, the importance of building trust in biosimilars, and the legislative changes needed to ensure safe, effective, and affordable treatments for all. Tune in for actionable insights and real-world stories that matter to patients, providers, and policymakers alike.